Cambium Bio Ltd (CMB) - Total Liabilities
Based on the latest financial reports, Cambium Bio Ltd (CMB) has total liabilities worth AU$1.46 Million AUD (≈ $1.03 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CMB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Cambium Bio Ltd - Total Liabilities Trend (1999–2025)
This chart illustrates how Cambium Bio Ltd's total liabilities have evolved over time, based on quarterly financial data. See CMB cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Cambium Bio Ltd Competitors by Total Liabilities
The table below lists competitors of Cambium Bio Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FBS Global Limited Ordinary Shares
NASDAQ:FBGL
|
USA | $14.90 Million |
|
Finexia Financial Group Ltd
AU:FNX
|
Australia | AU$134.96 Million |
|
Tourn International AB
ST:TOURN
|
Sweden | Skr20.46 Million |
|
Morgan Advanced Materials plc
LSE:MGAM
|
UK | GBX668.20 Million |
|
HWH International Inc
NASDAQ:HWH
|
USA | $1.88 Million |
|
XOX Bhd
KLSE:0165
|
Malaysia | RM188.00 Million |
|
paragon GmbH & Co. KGaA
F:PGN
|
Germany | €106.61 Million |
|
IMAGIS Co. Ltd
KQ:115610
|
Korea | ₩4.42 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Cambium Bio Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cambium Bio Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cambium Bio Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cambium Bio Ltd (1999–2025)
The table below shows the annual total liabilities of Cambium Bio Ltd from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.46 Million ≈ $1.03 Million |
-49.21% |
| 2024-06-30 | AU$2.87 Million ≈ $2.03 Million |
-35.22% |
| 2023-06-30 | AU$4.43 Million ≈ $3.14 Million |
+199.65% |
| 2022-06-30 | AU$1.48 Million ≈ $1.05 Million |
-66.09% |
| 2021-06-30 | AU$4.36 Million ≈ $3.09 Million |
+18.12% |
| 2020-06-30 | AU$3.70 Million ≈ $2.61 Million |
-58.61% |
| 2019-06-30 | AU$8.93 Million ≈ $6.32 Million |
+333.13% |
| 2018-06-30 | AU$2.06 Million ≈ $1.46 Million |
+93.57% |
| 2017-06-30 | AU$1.06 Million ≈ $753.49K |
-7.41% |
| 2016-06-30 | AU$1.15 Million ≈ $813.75K |
-12.02% |
| 2015-06-30 | AU$1.31 Million ≈ $924.88K |
-33.00% |
| 2014-06-30 | AU$1.95 Million ≈ $1.38 Million |
-71.69% |
| 2013-06-30 | AU$6.89 Million ≈ $4.88 Million |
+411.44% |
| 2012-06-30 | AU$1.35 Million ≈ $953.52K |
+45.97% |
| 2011-06-30 | AU$923.21K ≈ $653.23K |
+105.16% |
| 2010-06-30 | AU$450.00K ≈ $318.40K |
-95.34% |
| 2002-06-30 | AU$9.67 Million ≈ $6.84 Million |
-92.52% |
| 2001-06-30 | AU$129.20 Million ≈ $91.42 Million |
+0.72% |
| 2000-06-30 | AU$128.27 Million ≈ $90.76 Million |
-14.97% |
| 1999-06-30 | AU$150.86 Million ≈ $106.74 Million |
-- |
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more